Elizabeth M. Crone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth M. Crone has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bernhard Riedel
5 shared publications- David J. Byrne
Peter MacCallum Cancer Centre
5 shared publications David M. Shackleford
5 shared publicationsJia-Min B. Pang
5 shared publications- Kwok Ming Ho
The Chinese University of Hong Kong
5 shared publications - Michael A. Henderson
Division of Cancer Surgery Peter MacCallum Cancer Centre Melbourne Victoria Australia
5 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e89596
Centering Equity During Health Technology Innovation: Scoping Review of Methods and Research Adjustments to Promote Inclusive Coproduction.
Digital health has the potential to mitigate health inequity for priority populations who are underserved or marginalized by the health system. However, there is a lack of practical guidance on how to include priority communities in the coproduction of digital health technologies, particularly across the entire lifecycle of innovation, including research, development, and evaluation. The aim of this scoping review was to systematically identify and assess published methods used during digital health innovation to promote equitable inclusion of priority communities at every stage of the Centre for eHealth Research roadmap for digital health technologies. This review was based on the Arksey and O'Malley framework for scoping reviews. A 6-stage framework was used to execute the review. To increase the trustworthiness of the findings, an expert advisory group was consulted, and their feedback incorporated into the final manuscript. The Participant, Concept, and Context framework was used to structure the inclusion criteria. The review identified a total of 106 articles, 58 methods, 4 approaches, and 17 research adjustments used to coproduce digital health technologies with priority communities. Common methods across multiple stages included interviews, focus groups, surveys, and workshops; however, the most accessible way to make equity a practical reality during health technology innovation is to appoint a priority population community advisor, or advisory group, from project inception to project closure. Visual and creative methods like photovoice, home tours, and body-mapping were also used, often by priority population researchers themselves. Research adjustments that promote patient safety and comfort, enhanced literacy, peer-support, and recognize sociocultural and demographic considerations have been used to increase the inclusion of priority populations during digital health innovation. Embedding equity is possible using the practical methods and research adjustments identified to promote inclusive coproduction. Professionals working across health care, health informatics, research, digital health, and technology development can use these findings to center digital health equity during technology innovation. This research also recognizes that coproduction must draw on epistemological frameworks, or ways of thinking, which support Indigenous and other priority population knowledge systems. A solely Western lens risks reinforcing structural barriers and overlooking essential knowledge, as demonstrated by this review when the search strategy missed key scholarly works by priority population authors themselves.
- 3 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e89596
Open AccessCentering Equity During Health Technology Innovation: Scoping Review of Methods and Research Adjustments to Promote Inclusive Coproduction.
Digital health has the potential to mitigate health inequity for priority populations who are underserved or marginalized by the health system. However, there is a lack of practical guidance on how to include priority communities in the coproduction of digital health technologies, particularly across the entire lifecycle of innovation, including research, development, and evaluation. The aim of this scoping review was to systematically identify and assess published methods used during digital health innovation to promote equitable inclusion of priority communities at every stage of the Centre for eHealth Research roadmap for digital health technologies. This review was based on the Arksey and O'Malley framework for scoping reviews. A 6-stage framework was used to execute the review. To increase the trustworthiness of the findings, an expert advisory group was consulted, and their feedback incorporated into the final manuscript. The Participant, Concept, and Context framework was used to structure the inclusion criteria. The review identified a total of 106 articles, 58 methods, 4 approaches, and 17 research adjustments used to coproduce digital health technologies with priority communities. Common methods across multiple stages included interviews, focus groups, surveys, and workshops; however, the most accessible way to make equity a practical reality during health technology innovation is to appoint a priority population community advisor, or advisory group, from project inception to project closure. Visual and creative methods like photovoice, home tours, and body-mapping were also used, often by priority population researchers themselves. Research adjustments that promote patient safety and comfort, enhanced literacy, peer-support, and recognize sociocultural and demographic considerations have been used to increase the inclusion of priority populations during digital health innovation. Embedding equity is possible using the practical methods and research adjustments identified to promote inclusive coproduction. Professionals working across health care, health informatics, research, digital health, and technology development can use these findings to center digital health equity during technology innovation. This research also recognizes that coproduction must draw on epistemological frameworks, or ways of thinking, which support Indigenous and other priority population knowledge systems. A solely Western lens risks reinforcing structural barriers and overlooking essential knowledge, as demonstrated by this review when the search strategy missed key scholarly works by priority population authors themselves.
- Open Access
- 30 December 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (1) , 1-14
Equity in cancer care: mixed methods clinical utility analysis of the Nursing Equity Assessment Tool (NEAT) to identify disadvantage in newly diagnosed cancer patients
Purpose Individuals who experience complex biomedical factors and poorer social determinants of health (SDoH) have worse cancer outcomes than other people with cancer. This study appraised the clinical utility of the Nursing Equity Assessment Tool (NEAT), designed to facilitate early and systematic identification of such factors to optimise timely referral for support. Methods A prospective, mixed-methods case-series study was conducted at a specialist cancer centre. The NEAT comprises 15 items mapping to four biopsychosocial domains. Clinical nurse consultants (CNCs) completed the NEAT with newly diagnosed patients during consultations. Semi-structured interviews exploring clinical utility aspects (appropriateness, acceptability, and practicability) were undertaken with patients at 2 weeks, and CNCs at 12- and 24-week post-completion of the NEAT; then analysed using qualitative content analysis. Participant characteristics were collected via self-report and medical records. Patient-reported outcome measures were completed prior to interviews. Healthcare utilisation data were gathered 12- and 24-week post-completion of the NEAT. Quantitative data were analysed descriptively using measures of association. Results Thirty-seven patients and seven CNCs participated. All participants considered the NEAT highly acceptable and appropriate, with potential to improve patient outcomes. Feedback recommended refinements to content and CNC training. Implementation considerations included advocacy for service investment to enable timely receipt of support to address disadvantage. Conclusions Patients and CNCs considered this novel point-of-care tool was acceptable, appropriate, and demonstrated promise to help quickly identify and address newly diagnosed cancer patients at risk of complex care needs stemming from medical and non-medical factors.
- 30 December 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (1) , 1-14
Open AccessEquity in cancer care: mixed methods clinical utility analysis of the Nursing Equity Assessment Tool (NEAT) to identify disadvantage in newly diagnosed cancer patients
Purpose Individuals who experience complex biomedical factors and poorer social determinants of health (SDoH) have worse cancer outcomes than other people with cancer. This study appraised the clinical utility of the Nursing Equity Assessment Tool (NEAT), designed to facilitate early and systematic identification of such factors to optimise timely referral for support. Methods A prospective, mixed-methods case-series study was conducted at a specialist cancer centre. The NEAT comprises 15 items mapping to four biopsychosocial domains. Clinical nurse consultants (CNCs) completed the NEAT with newly diagnosed patients during consultations. Semi-structured interviews exploring clinical utility aspects (appropriateness, acceptability, and practicability) were undertaken with patients at 2 weeks, and CNCs at 12- and 24-week post-completion of the NEAT; then analysed using qualitative content analysis. Participant characteristics were collected via self-report and medical records. Patient-reported outcome measures were completed prior to interviews. Healthcare utilisation data were gathered 12- and 24-week post-completion of the NEAT. Quantitative data were analysed descriptively using measures of association. Results Thirty-seven patients and seven CNCs participated. All participants considered the NEAT highly acceptable and appropriate, with potential to improve patient outcomes. Feedback recommended refinements to content and CNC training. Implementation considerations included advocacy for service investment to enable timely receipt of support to address disadvantage. Conclusions Patients and CNCs considered this novel point-of-care tool was acceptable, appropriate, and demonstrated promise to help quickly identify and address newly diagnosed cancer patients at risk of complex care needs stemming from medical and non-medical factors.
- Open Access
- 9 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48432
Clinical Utility Assessment of a Nursing Checklist Identifying Complex Care Needs Due to Inequities Among Ambulatory Patients With Cancer: Protocol for a Mixed Methods Study
Background: Disparities in cancer incidence, complex care needs, and poor health outcomes are largely driven by structural inequities stemming from social determinants of health. To date, no evidence-based clinical tool has been developed to identify newly diagnosed patients at risk of poorer outcomes. Specialist cancer nurses are well-positioned to ameliorate inequity of opportunity for optimal care, treatment, and outcomes through timely screening, assessment, and intervention. We designed a nursing complexity checklist (the “Checklist”) to support these activities, with the ultimate goal of improving equitable experiences and outcomes of care. This study aims to generate evidence regarding the clinical utility of the Checklist. Objective: The primary objectives of this study are to provide qualitative evidence regarding key aspects of the Checklist’s clinical utility (appropriateness, acceptability, and practicability), informed by Smart’s multidimensional model of clinical utility. Secondary objectives explore the predictive value of the Checklist and concordance between specific checklist items and patient-reported outcome measures. Methods: This prospective mixed methods case series study will recruit up to 60 newly diagnosed patients with cancer and 10 specialist nurses from a specialist cancer center. Nurses will complete the Checklist with patient participants. Within 2 weeks of Checklist completion, patients will complete 5 patient-reported outcome measures with established psychometric properties that correspond to specific checklist items and an individual semistructured interview to explore Checklist clinical utility. Interviews with nurses will occur 12 and 24 weeks after they first complete a checklist, exploring perceptions of the Checklist’s clinical utility including barriers and facilitators to implementation. Data describing planned and unplanned patient service use will be collected from patient follow-up interviews at 12 weeks and the electronic medical record at 24 weeks after Checklist completion. Descriptive statistics will summarize operational, checklist, and electronic medical record data. The predictive value of the Checklist and the relationship between specific checklist items and relevant patient-reported outcome measures will be examined using descriptive statistics, contingency tables, measures of association, and plots as appropriate. Qualitative data will be analyzed using a content analysis approach. Results: This study was approved by the institution’s ethics committee. The enrollment period commenced in May 2022 and ended in November 2022. In total, 37 patients with cancer and 7 specialist cancer nurses were recruited at this time. Data collection is scheduled for completion at the end of May 2023. Conclusions: This study will evaluate key clinical utility dimensions of a nursing complexity checklist. It will also provide preliminary evidence on its predictive value and information to support its seamless implementation into everyday practice including, but not limited to, possible revisions to the Checklist, instructions, and training for relevant personnel. Future implementation of this Checklist may improve equity of opportunity of access to care for patients with cancer. International Registered Report Identifier (IRRID): DERR1-10.2196/48432
- 9 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48432
Open AccessClinical Utility Assessment of a Nursing Checklist Identifying Complex Care Needs Due to Inequities Among Ambulatory Patients With Cancer: Protocol for a Mixed Methods Study
Background: Disparities in cancer incidence, complex care needs, and poor health outcomes are largely driven by structural inequities stemming from social determinants of health. To date, no evidence-based clinical tool has been developed to identify newly diagnosed patients at risk of poorer outcomes. Specialist cancer nurses are well-positioned to ameliorate inequity of opportunity for optimal care, treatment, and outcomes through timely screening, assessment, and intervention. We designed a nursing complexity checklist (the “Checklist”) to support these activities, with the ultimate goal of improving equitable experiences and outcomes of care. This study aims to generate evidence regarding the clinical utility of the Checklist. Objective: The primary objectives of this study are to provide qualitative evidence regarding key aspects of the Checklist’s clinical utility (appropriateness, acceptability, and practicability), informed by Smart’s multidimensional model of clinical utility. Secondary objectives explore the predictive value of the Checklist and concordance between specific checklist items and patient-reported outcome measures. Methods: This prospective mixed methods case series study will recruit up to 60 newly diagnosed patients with cancer and 10 specialist nurses from a specialist cancer center. Nurses will complete the Checklist with patient participants. Within 2 weeks of Checklist completion, patients will complete 5 patient-reported outcome measures with established psychometric properties that correspond to specific checklist items and an individual semistructured interview to explore Checklist clinical utility. Interviews with nurses will occur 12 and 24 weeks after they first complete a checklist, exploring perceptions of the Checklist’s clinical utility including barriers and facilitators to implementation. Data describing planned and unplanned patient service use will be collected from patient follow-up interviews at 12 weeks and the electronic medical record at 24 weeks after Checklist completion. Descriptive statistics will summarize operational, checklist, and electronic medical record data. The predictive value of the Checklist and the relationship between specific checklist items and relevant patient-reported outcome measures will be examined using descriptive statistics, contingency tables, measures of association, and plots as appropriate. Qualitative data will be analyzed using a content analysis approach. Results: This study was approved by the institution’s ethics committee. The enrollment period commenced in May 2022 and ended in November 2022. In total, 37 patients with cancer and 7 specialist cancer nurses were recruited at this time. Data collection is scheduled for completion at the end of May 2023. Conclusions: This study will evaluate key clinical utility dimensions of a nursing complexity checklist. It will also provide preliminary evidence on its predictive value and information to support its seamless implementation into everyday practice including, but not limited to, possible revisions to the Checklist, instructions, and training for relevant personnel. Future implementation of this Checklist may improve equity of opportunity of access to care for patients with cancer. International Registered Report Identifier (IRRID): DERR1-10.2196/48432
- Open Access
- 23 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Clinical Utility Assessment of a Nursing Checklist Identifying Complex Care Needs Due to Inequities Among Ambulatory Patients With Cancer: Protocol for a Mixed Methods Study (Preprint)
BACKGROUND Disparities in cancer incidence, complex care needs, and poor health outcomes are largely driven by structural inequities stemming from social determinants of health. To date, no evidence-based clinical tool has been developed to identify newly diagnosed patients at risk of poorer outcomes. Specialist cancer nurses are well-positioned to ameliorate inequity of opportunity for optimal care, treatment, and outcomes through timely screening, assessment, and intervention. We designed a nursing complexity checklist (the “Checklist”) to support these activities, with the ultimate goal of improving equitable experiences and outcomes of care. This study aims to generate evidence regarding the clinical utility of the Checklist. OBJECTIVE The primary objectives of this study are to provide qualitative evidence regarding key aspects of the Checklist’s clinical utility (appropriateness, acceptability, and practicability), informed by Smart’s multidimensional model of clinical utility. Secondary objectives explore the predictive value of the Checklist and concordance between specific checklist items and patient-reported outcome measures. METHODS This prospective mixed methods case series study will recruit up to 60 newly diagnosed patients with cancer and 10 specialist nurses from a specialist cancer center. Nurses will complete the Checklist with patient participants. Within 2 weeks of Checklist completion, patients will complete 5 patient-reported outcome measures with established psychometric properties that correspond to specific checklist items and an individual semistructured interview to explore Checklist clinical utility. Interviews with nurses will occur 12 and 24 weeks after they first complete a checklist, exploring perceptions of the Checklist’s clinical utility including barriers and facilitators to implementation. Data describing planned and unplanned patient service use will be collected from patient follow-up interviews at 12 weeks and the electronic medical record at 24 weeks after Checklist completion. Descriptive statistics will summarize operational, checklist, and electronic medical record data. The predictive value of the Checklist and the relationship between specific checklist items and relevant patient-reported outcome measures will be examined using descriptive statistics, contingency tables, measures of association, and plots as appropriate. Qualitative data will be analyzed using a content analysis approach. RESULTS This study was approved by the institution’s ethics committee. The enrollment period commenced in May 2022 and ended in November 2022. In total, 37 patients with cancer and 7 specialist cancer nurses were recruited at this time. Data collection is scheduled for completion at the end of May 2023. CONCLUSIONS This study will evaluate key clinical utility dimensions of a nursing complexity checklist. It will also provide preliminary evidence on its predictive value and information to support its seamless implementation into everyday practice including, but not limited to, possible revisions to the Checklist, instructions, and training for relevant personnel. Future implementation of this Checklist may improve equity of opportunity of access to care for patients with cancer. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48432
- 23 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessClinical Utility Assessment of a Nursing Checklist Identifying Complex Care Needs Due to Inequities Among Ambulatory Patients With Cancer: Protocol for a Mixed Methods Study (Preprint)
BACKGROUND Disparities in cancer incidence, complex care needs, and poor health outcomes are largely driven by structural inequities stemming from social determinants of health. To date, no evidence-based clinical tool has been developed to identify newly diagnosed patients at risk of poorer outcomes. Specialist cancer nurses are well-positioned to ameliorate inequity of opportunity for optimal care, treatment, and outcomes through timely screening, assessment, and intervention. We designed a nursing complexity checklist (the “Checklist”) to support these activities, with the ultimate goal of improving equitable experiences and outcomes of care. This study aims to generate evidence regarding the clinical utility of the Checklist. OBJECTIVE The primary objectives of this study are to provide qualitative evidence regarding key aspects of the Checklist’s clinical utility (appropriateness, acceptability, and practicability), informed by Smart’s multidimensional model of clinical utility. Secondary objectives explore the predictive value of the Checklist and concordance between specific checklist items and patient-reported outcome measures. METHODS This prospective mixed methods case series study will recruit up to 60 newly diagnosed patients with cancer and 10 specialist nurses from a specialist cancer center. Nurses will complete the Checklist with patient participants. Within 2 weeks of Checklist completion, patients will complete 5 patient-reported outcome measures with established psychometric properties that correspond to specific checklist items and an individual semistructured interview to explore Checklist clinical utility. Interviews with nurses will occur 12 and 24 weeks after they first complete a checklist, exploring perceptions of the Checklist’s clinical utility including barriers and facilitators to implementation. Data describing planned and unplanned patient service use will be collected from patient follow-up interviews at 12 weeks and the electronic medical record at 24 weeks after Checklist completion. Descriptive statistics will summarize operational, checklist, and electronic medical record data. The predictive value of the Checklist and the relationship between specific checklist items and relevant patient-reported outcome measures will be examined using descriptive statistics, contingency tables, measures of association, and plots as appropriate. Qualitative data will be analyzed using a content analysis approach. RESULTS This study was approved by the institution’s ethics committee. The enrollment period commenced in May 2022 and ended in November 2022. In total, 37 patients with cancer and 7 specialist cancer nurses were recruited at this time. Data collection is scheduled for completion at the end of May 2023. CONCLUSIONS This study will evaluate key clinical utility dimensions of a nursing complexity checklist. It will also provide preliminary evidence on its predictive value and information to support its seamless implementation into everyday practice including, but not limited to, possible revisions to the Checklist, instructions, and training for relevant personnel. Future implementation of this Checklist may improve equity of opportunity of access to care for patients with cancer. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48432
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose:The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer.Patients and Methods:In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor.Results:Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells.Conclusions:One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.See related commentary by Blaes et al., p. 1781
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose:The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer.Patients and Methods:In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor.Results:Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells.Conclusions:One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.See related commentary by Blaes et al., p. 1781
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose:The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer.Patients and Methods:In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor.Results:Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells.Conclusions:One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.See related commentary by Blaes et al., p. 1781
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose:The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer.Patients and Methods:In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor.Results:Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells.Conclusions:One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival.See related commentary by Blaes et al., p. 1781
- 15 April 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (8) , 1803-1811
Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose: The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer. Patients and Methods: In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor. Results: Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells. Conclusions: One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival. See related commentary by Blaes et al., p. 1781
- 15 April 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (8) , 1803-1811
Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
Purpose: The majority of deaths from breast cancer occur following the development of metastatic disease, a process inhibited by β-blockers in preclinical studies. This phase II randomized controlled trial evaluated the effect of preoperative β-blockade with propranolol on biomarkers of metastatic potential and the immune cell profile within the primary tumor of patients with breast cancer. Patients and Methods: In this triple-blind placebo-controlled clinical trial, 60 patients were randomly assigned to receive an escalating dose of oral propranolol (n = 30; 80–160 mg daily) or placebo (n = 30) for 7 days prior to surgery. The primary endpoint investigated the effect of propranolol on prometastatic and proinflammatory gene expression within the primary tumor. Results: Propranolol downregulated primary tumor expression of mesenchymal genes (P = 0.002) without affecting epithelial gene expression (P = 0.21). Bioinformatic analyses implicated downregulation of Snail/Slug (P = 0.03), NF-κB/Rel (P < 0.01), and AP-1 (P < 0.01) transcription factors in structuring the observed transcriptome alterations, and identified changes in intratumoral neutrophil, natural killer cell, and dendritic cell recruitment (all P < 0.01). Patients with clinical evidence of drug response (lowered heart rate and blood pressure) demonstrated elevated tumor infiltration of CD68+ macrophages and CD8+ T cells. Conclusions: One week of β-blockade with propranolol reduced intratumoral mesenchymal polarization and promoted immune cell infiltration in early-stage surgically-resectable breast cancer. These results show that β-blockade reduces biomarkers associated with metastatic potential, and support the need for larger phase III clinical trials powered to detect the impact of β-blockade on cancer recurrence and survival. See related commentary by Blaes et al., p. 1781
- Open Access
- 24 February 2011
- Published by Springer Nature in Osteoporosis International
- Vol. 23 (2) , 553-562
Fasting and postprandial spot urine calcium-to-creatinine ratios do not detect hypercalciuria
Summary Clinicians can diagnose high urine calcium by asking patients to collect urine for 24 h or to provide a random urine specimen. In this study, random urine calcium levels were not as accurate as those from the 24-h collection. Clinicians should only use 24-h collections to diagnose high urine calcium. Introduction Clinicians diagnose hypercalciuria using a 24-h urine calcium (24HUC) or a spot urine-calcium-to-creatinine ratio (SUCCR) specimen. The SUCCR is reportedly interchangeable with the 24HUC. However, studies to date show mixed results when comparing SUCCR and 24HUC values. We systematically compared fasting and postprandial SUCCR measurements to 24HUC measurements using Bland–Altman analysis. Methods Twenty-one postmenopausal women aged 58 ± 7 years came to the research ward for three 24-h inpatient stays. At each study visit, research nurses collected fasting morning (n = 62) and postprandial (n = 62) spot urine specimens along with carefully timed and complete 24-h urine specimens (n = 63) from each woman. Results Hypercalciuria was present in 13 24HUC samples (21%) using an upper limit of 250 mg/24-h. The fasting SUCCR underestimated the 24HUC (Bland–Altman bias −71 mg/24-h), with a sensitivity and specificity for diagnosing hypercalciuria of 0% and 98%, respectively. The postprandial SUCCR overestimated the 24HUC (Bland–Altman bias +61 mg/24-h), with a sensitivity and specificity of 77% and 61%, respectively. The average of fasting and postprandial SUCCR measurements had a lower Bland–Altman bias of −3 mg/24-h but demonstrated a sensitivity and specificity of only 42% and 78%, respectively. Conclusions The SUCCR is not interchangeable with the 24HUC. The fasting SUCCR systematically underestimates, and the postprandial SUCCR systematically overestimates, 24HUC. The average SUCCR demonstrates low sensitivity and specificity for hypercalciuria. Clinicians must use the 24HUC to diagnose hypercalciuria in postmenopausal women.
- 24 February 2011
- Published by Springer Nature in Osteoporosis International
- Vol. 23 (2) , 553-562
Open AccessFasting and postprandial spot urine calcium-to-creatinine ratios do not detect hypercalciuria
Summary Clinicians can diagnose high urine calcium by asking patients to collect urine for 24 h or to provide a random urine specimen. In this study, random urine calcium levels were not as accurate as those from the 24-h collection. Clinicians should only use 24-h collections to diagnose high urine calcium. Introduction Clinicians diagnose hypercalciuria using a 24-h urine calcium (24HUC) or a spot urine-calcium-to-creatinine ratio (SUCCR) specimen. The SUCCR is reportedly interchangeable with the 24HUC. However, studies to date show mixed results when comparing SUCCR and 24HUC values. We systematically compared fasting and postprandial SUCCR measurements to 24HUC measurements using Bland–Altman analysis. Methods Twenty-one postmenopausal women aged 58 ± 7 years came to the research ward for three 24-h inpatient stays. At each study visit, research nurses collected fasting morning (n = 62) and postprandial (n = 62) spot urine specimens along with carefully timed and complete 24-h urine specimens (n = 63) from each woman. Results Hypercalciuria was present in 13 24HUC samples (21%) using an upper limit of 250 mg/24-h. The fasting SUCCR underestimated the 24HUC (Bland–Altman bias −71 mg/24-h), with a sensitivity and specificity for diagnosing hypercalciuria of 0% and 98%, respectively. The postprandial SUCCR overestimated the 24HUC (Bland–Altman bias +61 mg/24-h), with a sensitivity and specificity of 77% and 61%, respectively. The average of fasting and postprandial SUCCR measurements had a lower Bland–Altman bias of −3 mg/24-h but demonstrated a sensitivity and specificity of only 42% and 78%, respectively. Conclusions The SUCCR is not interchangeable with the 24HUC. The fasting SUCCR systematically underestimates, and the postprandial SUCCR systematically overestimates, 24HUC. The average SUCCR demonstrates low sensitivity and specificity for hypercalciuria. Clinicians must use the 24HUC to diagnose hypercalciuria in postmenopausal women.